XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements (Tables)

Royalty and Commercial Payment Purchase Agreements (Tables)

9 Months Ended

Sep. 30, 2023

Royalty and Commercial Payment Purchase Agreements

Summary of royalty and commercial payment receivable activities

The following table summarizes the royalty and commercial payment receivable activities during the nine months ended September 30, 2023 (in thousands):


		Short-Term		Long-Term
Balance at January 1, 2023		$	2,366	$	63,683
Acquisition of royalty and commercial payment receivables:
Aptevo			—		9,650
LadRx			—		6,000
Receipt of royalty and commercial payments:
Affitech			(7,284)		—
Aptevo			—		(1,144)
Impairment of royalty and commercial payment receivables:
Bioasis			—		(1,575)
Reclassification to short-term royalty and commercial payment receivables:
Affitech			4,918		(4,918)
Recognition of contingent consideration:
Affitech			—		3,000
Balance at September 30, 2023		$	—	$	74,696